FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4313207619> ?p ?o ?g. }

• W4313207619 endingPage "457" @default.
• W4313207619 startingPage "439" @default.
• W4313207619 abstract "Gemcitabine is a broad-spectrum antimetabolite and a deoxycytidine analog recognized as a standard therapy alone or in combination with other antineoplastic agents in the therapy of pancreas cancer. Drug resistance following gemcitabine treatment is a common phenomenon; therefore, combinational therapy models are usually preferred. Pancreatic ductal adenocarcinoma, or pancreas cancer, is the fourth leading cause of cancer-related deaths worldwide. With the increasing incidence of pancreatic cancer every year, the mortality rate is also rising significantly because of late diagnosis, and limited chemotherapy options. Adjuvant chemotherapy after surgical resection is the typical option for the treatment of early pancreatic cancer. Mostly, 5-fluorouracil/leucovorin with irinotecan and oxaliplatin (FOLFIRINOX) and gemcitabine/nab-paclitaxel is used for the prognosis of advanced pancreatic cancer; however, chemoresistance usually occurs limiting the effectiveness of the chemotherapy. Therefore, most of the studies are focused on gemcitabine combination with other drugs to overcome the situation. As an apoptotic agent and a member of brassinosteroids, epibrassinolide (EBR) induces endoplasmic reticulum (ER) stress-dependent cell death in different cancer cells, as shown by our group. In this study, we aimed to enhance the gemcitabine apoptotic effect by EBR combined treatment in pancreatic cancer cells. EBR treatment reduced cell viability and inhibited cell proliferation in PANC-1, MIA PaCa-2, and AsPC-1 cells. Each pancreatic cancer cell gave different responses to the EBR treatment because of different aggressiveness. However, EBR induced apoptosis through increasing ROS generation, which was associated with ER stress in PANC-1 and MIA PaCa-2 cells. Gemcitabine alone reduced the cell viability of each pancreatic cancer cell line; however, combination with EBR led to further induction of apoptotic cell death in each pancreatic cancer cell line. In addition, combined treatment of gemcitabine and EBR further decreased N-cadherin and vimentin expressions, suggesting that epithelial-mesenchymal transition of pancreatic cells is reduced. In conclusion, EBR had therapeutic potential to avoid the gemcitabine-induced side effects during the treatment of pancreatic cancer." @default.
• W4313207619 created "2023-01-06" @default.
• W4313207619 creator A5006518029 @default.
• W4313207619 creator A5008477996 @default.
• W4313207619 creator A5024011837 @default.
• W4313207619 creator A5041626064 @default.
• W4313207619 creator A5049202052 @default.
• W4313207619 creator A5053140470 @default.
• W4313207619 creator A5055952166 @default.
• W4313207619 creator A5065205112 @default.
• W4313207619 creator A5066885758 @default.
• W4313207619 creator A5072793948 @default.
• W4313207619 creator A5090661470 @default.
• W4313207619 date "2022-01-01" @default.
• W4313207619 modified "2023-10-14" @default.
• W4313207619 title "Gemcitabine in combination with epibrassinolide enhanced the apoptotic response in an ER stress-dependent manner and reduced the epithelial-mesenchymal transition in pancreatic cancer cells" @default.
• W4313207619 cites W1194999709 @default.
• W4313207619 cites W1822477452 @default.
• W4313207619 cites W1824149364 @default.
• W4313207619 cites W183556408 @default.
• W4313207619 cites W1976563274 @default.
• W4313207619 cites W1991370238 @default.
• W4313207619 cites W2029242108 @default.
• W4313207619 cites W2037864697 @default.
• W4313207619 cites W2056129497 @default.
• W4313207619 cites W2075181827 @default.
• W4313207619 cites W2101259861 @default.
• W4313207619 cites W2126654004 @default.
• W4313207619 cites W2160367631 @default.
• W4313207619 cites W2168992025 @default.
• W4313207619 cites W2192080449 @default.
• W4313207619 cites W2196607495 @default.
• W4313207619 cites W2284799106 @default.
• W4313207619 cites W2317877264 @default.
• W4313207619 cites W2566221317 @default.
• W4313207619 cites W2581734969 @default.
• W4313207619 cites W2768466792 @default.
• W4313207619 cites W2786935026 @default.
• W4313207619 cites W2887052571 @default.
• W4313207619 cites W2887566254 @default.
• W4313207619 cites W2889052898 @default.
• W4313207619 cites W2893838704 @default.
• W4313207619 cites W2896652675 @default.
• W4313207619 cites W2898368508 @default.
• W4313207619 cites W2912742022 @default.
• W4313207619 cites W2963199063 @default.
• W4313207619 cites W2990459652 @default.
• W4313207619 cites W3010591636 @default.
• W4313207619 cites W3016050153 @default.
• W4313207619 cites W3018333662 @default.
• W4313207619 cites W3035187994 @default.
• W4313207619 cites W3035577851 @default.
• W4313207619 doi "https://doi.org/10.55730/1300-0152.2630" @default.
• W4313207619 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37529796" @default.
• W4313207619 hasPublicationYear "2022" @default.
• W4313207619 type Work @default.
• W4313207619 citedByCount "0" @default.
• W4313207619 crossrefType "journal-article" @default.
• W4313207619 hasAuthorship W4313207619A5006518029 @default.
• W4313207619 hasAuthorship W4313207619A5008477996 @default.
• W4313207619 hasAuthorship W4313207619A5024011837 @default.
• W4313207619 hasAuthorship W4313207619A5041626064 @default.
• W4313207619 hasAuthorship W4313207619A5049202052 @default.
• W4313207619 hasAuthorship W4313207619A5053140470 @default.
• W4313207619 hasAuthorship W4313207619A5055952166 @default.
• W4313207619 hasAuthorship W4313207619A5065205112 @default.
• W4313207619 hasAuthorship W4313207619A5066885758 @default.
• W4313207619 hasAuthorship W4313207619A5072793948 @default.
• W4313207619 hasAuthorship W4313207619A5090661470 @default.
• W4313207619 hasBestOaLocation W43132076191 @default.
• W4313207619 hasConcept C121608353 @default.
• W4313207619 hasConcept C126322002 @default.
• W4313207619 hasConcept C143998085 @default.
• W4313207619 hasConcept C2776694085 @default.
• W4313207619 hasConcept C2776999253 @default.
• W4313207619 hasConcept C2777148230 @default.
• W4313207619 hasConcept C2780210213 @default.
• W4313207619 hasConcept C2780258809 @default.
• W4313207619 hasConcept C2780259306 @default.
• W4313207619 hasConcept C2780962732 @default.
• W4313207619 hasConcept C502942594 @default.
• W4313207619 hasConcept C526805850 @default.
• W4313207619 hasConcept C71924100 @default.
• W4313207619 hasConcept C86803240 @default.
• W4313207619 hasConcept C96232424 @default.
• W4313207619 hasConceptScore W4313207619C121608353 @default.
• W4313207619 hasConceptScore W4313207619C126322002 @default.
• W4313207619 hasConceptScore W4313207619C143998085 @default.
• W4313207619 hasConceptScore W4313207619C2776694085 @default.
• W4313207619 hasConceptScore W4313207619C2776999253 @default.
• W4313207619 hasConceptScore W4313207619C2777148230 @default.
• W4313207619 hasConceptScore W4313207619C2780210213 @default.
• W4313207619 hasConceptScore W4313207619C2780258809 @default.
• W4313207619 hasConceptScore W4313207619C2780259306 @default.
• W4313207619 hasConceptScore W4313207619C2780962732 @default.
• W4313207619 hasConceptScore W4313207619C502942594 @default.
• W4313207619 hasConceptScore W4313207619C526805850 @default.
• W4313207619 hasConceptScore W4313207619C71924100 @default.

• next